Roche licenses Alector Parkinson's therapy in deal worth up to $1.27 billion

Genentech will pay $100 million upfront and as much as $1.17 billion in milestones for worldwide rights to experimental AL050.

INDIAN MARKET GRID EDITORIAL DESK5 MIN READPUBLIC PREVIEW

MEMBER PREVIEW

Genentech will pay $100 million upfront and as much as $1.17 billion in milestones for worldwide rights to experimental AL050.

FREE MEMBER LOGIN

LOGIN TO CONTINUE READING.

Create or use your free IMG login to read standard articles. Important and Premium analysis also requires an active ₹99 or ₹199 plan.

The public preview and the member article share the same canonical page. No personalised investment recommendation is provided.